UniProt ID | FBRL_HUMAN | |
---|---|---|
UniProt AC | P22087 | |
Protein Name | rRNA 2'-O-methyltransferase fibrillarin | |
Gene Name | FBL | |
Organism | Homo sapiens (Human). | |
Sequence Length | 321 | |
Subcellular Localization | Nucleus, nucleolus . Fibrillar region of the nucleolus. | |
Protein Description | S-adenosyl-L-methionine-dependent methyltransferase that has the ability to methylate both RNAs and proteins. Involved in pre-rRNA processing by catalyzing the site-specific 2'-hydroxyl methylation of ribose moieties in pre-ribosomal RNA. Site specificity is provided by a guide RNA that base pairs with the substrate. Methylation occurs at a characteristic distance from the sequence involved in base pairing with the guide RNA. Also acts as a protein methyltransferase by mediating methylation of 'Gln-105' of histone H2A (H2AQ104me), a modification that impairs binding of the FACT complex and is specifically present at 35S ribosomal DNA locus. [PubMed: 24352239] | |
Protein Sequence | MKPGFSPRGGGFGGRGGFGDRGGRGGRGGFGGGRGRGGGFRGRGRGGGGGGGGGGGGGRGGGGFHSGGNRGRGRGGKRGNQSGKNVMVEPHRHEGVFICRGKEDALVTKNLVPGESVYGEKRVSISEGDDKIEYRAWNPFRSKLAAAILGGVDQIHIKPGAKVLYLGAASGTTVSHVSDIVGPDGLVYAVEFSHRSGRDLINLAKKRTNIIPVIEDARHPHKYRMLIAMVDVIFADVAQPDQTRIVALNAHTFLRNGGHFVISIKANCIDSTASAEAVFASEVKKMQQENMKPQEQLTLEPYERDHAVVVGVYRPPPKVKN | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
6 | Phosphorylation | --MKPGFSPRGGGFG --CCCCCCCCCCCCC | 21.43 | 21712546 | |
8 | Methylation | MKPGFSPRGGGFGGR CCCCCCCCCCCCCCC | 56.01 | - | |
8 | Asymmetric dimethylarginine | MKPGFSPRGGGFGGR CCCCCCCCCCCCCCC | 56.01 | - | |
15 | Methylation | RGGGFGGRGGFGDRG CCCCCCCCCCCCCCC | 42.30 | - | |
15 | Asymmetric dimethylarginine | RGGGFGGRGGFGDRG CCCCCCCCCCCCCCC | 42.30 | - | |
21 | Methylation | GRGGFGDRGGRGGRG CCCCCCCCCCCCCCC | 50.25 | - | |
21 | Asymmetric dimethylarginine | GRGGFGDRGGRGGRG CCCCCCCCCCCCCCC | 50.25 | - | |
24 | Methylation | GFGDRGGRGGRGGFG CCCCCCCCCCCCCCC | 47.41 | - | |
24 | Asymmetric dimethylarginine | GFGDRGGRGGRGGFG CCCCCCCCCCCCCCC | 47.41 | - | |
27 | Asymmetric dimethylarginine | DRGGRGGRGGFGGGR CCCCCCCCCCCCCCC | 44.90 | - | |
27 | Methylation | DRGGRGGRGGFGGGR CCCCCCCCCCCCCCC | 44.90 | - | |
34 | Methylation | RGGFGGGRGRGGGFR CCCCCCCCCCCCCCC | 34.60 | - | |
36 | Methylation | GFGGGRGRGGGFRGR CCCCCCCCCCCCCCC | 38.94 | - | |
45 | Ubiquitination | GGFRGRGRGGGGGGG CCCCCCCCCCCCCCC | 38.94 | 22817900 | |
45 | Methylation | GGFRGRGRGGGGGGG CCCCCCCCCCCCCCC | 38.94 | - | |
52 | Ubiquitination | RGGGGGGGGGGGGGR CCCCCCCCCCCCCCC | 34.54 | 23000965 | |
59 | Methylation | GGGGGGGRGGGGFHS CCCCCCCCCCCCCCC | 43.81 | - | |
64 | Ubiquitination | GGRGGGGFHSGGNRG CCCCCCCCCCCCCCC | 4.72 | 22817900 | |
70 | Methylation | GFHSGGNRGRGRGGK CCCCCCCCCCCCCCC | 39.19 | - | |
72 | Methylation | HSGGNRGRGRGGKRG CCCCCCCCCCCCCCC | 28.53 | - | |
74 | Ubiquitination | GGNRGRGRGGKRGNQ CCCCCCCCCCCCCCC | 49.70 | 22817900 | |
78 | Methylation | GRGRGGKRGNQSGKN CCCCCCCCCCCCCCC | 53.20 | - | |
82 | Phosphorylation | GGKRGNQSGKNVMVE CCCCCCCCCCCEEEC | 56.59 | 29214152 | |
84 | Sumoylation | KRGNQSGKNVMVEPH CCCCCCCCCEEECCC | 52.17 | 28112733 | |
84 | Ubiquitination | KRGNQSGKNVMVEPH CCCCCCCCCEEECCC | 52.17 | 32015554 | |
84 | Acetylation | KRGNQSGKNVMVEPH CCCCCCCCCEEECCC | 52.17 | 25953088 | |
99 | S-nitrosylation | RHEGVFICRGKEDAL CCCCEEEECCCCCEE | 2.97 | 19483679 | |
99 | S-nitrosocysteine | RHEGVFICRGKEDAL CCCCEEEECCCCCEE | 2.97 | - | |
101 | Ubiquitination | EGVFICRGKEDALVT CCEEEECCCCCEEEE | 33.04 | 27667366 | |
102 | Sumoylation | GVFICRGKEDALVTK CEEEECCCCCEEEEC | 32.82 | - | |
102 | Sumoylation | GVFICRGKEDALVTK CEEEECCCCCEEEEC | 32.82 | 28112733 | |
102 | Ubiquitination | GVFICRGKEDALVTK CEEEECCCCCEEEEC | 32.82 | 21906983 | |
102 | Acetylation | GVFICRGKEDALVTK CEEEECCCCCEEEEC | 32.82 | 26051181 | |
105 | Ubiquitination | ICRGKEDALVTKNLV EECCCCCEEEECCCC | 12.67 | 22817900 | |
108 | Ubiquitination | GKEDALVTKNLVPGE CCCCEEEECCCCCCC | 18.31 | 23000965 | |
109 | Sumoylation | KEDALVTKNLVPGES CCCEEEECCCCCCCC | 40.58 | - | |
109 | Sumoylation | KEDALVTKNLVPGES CCCEEEECCCCCCCC | 40.58 | 28112733 | |
109 | Ubiquitination | KEDALVTKNLVPGES CCCEEEECCCCCCCC | 40.58 | 23000965 | |
109 | Acetylation | KEDALVTKNLVPGES CCCEEEECCCCCCCC | 40.58 | 25953088 | |
116 | Phosphorylation | KNLVPGESVYGEKRV CCCCCCCCCCCCCEE | 26.93 | 23401153 | |
118 | Phosphorylation | LVPGESVYGEKRVSI CCCCCCCCCCCEEEE | 28.93 | 28152594 | |
120 | Ubiquitination | PGESVYGEKRVSISE CCCCCCCCCEEEECC | 21.72 | 22817900 | |
121 | Ubiquitination | GESVYGEKRVSISEG CCCCCCCCEEEECCC | 54.45 | 21906983 | |
121 | Acetylation | GESVYGEKRVSISEG CCCCCCCCEEEECCC | 54.45 | 30540930 | |
121 | 2-Hydroxyisobutyrylation | GESVYGEKRVSISEG CCCCCCCCEEEECCC | 54.45 | - | |
124 | Phosphorylation | VYGEKRVSISEGDDK CCCCCEEEECCCCCC | 25.16 | 29255136 | |
126 | Phosphorylation | GEKRVSISEGDDKIE CCCEEEECCCCCCEE | 28.20 | 30266825 | |
130 | Ubiquitination | VSISEGDDKIEYRAW EEECCCCCCEEEEEC | 65.77 | 22817900 | |
131 | Ubiquitination | SISEGDDKIEYRAWN EECCCCCCEEEEECC | 42.02 | 21906983 | |
131 | Acetylation | SISEGDDKIEYRAWN EECCCCCCEEEEECC | 42.02 | 25953088 | |
131 | 2-Hydroxyisobutyrylation | SISEGDDKIEYRAWN EECCCCCCEEEEECC | 42.02 | - | |
131 | Sumoylation | SISEGDDKIEYRAWN EECCCCCCEEEEECC | 42.02 | 28112733 | |
134 | Phosphorylation | EGDDKIEYRAWNPFR CCCCCEEEEECCHHH | 14.76 | 23403867 | |
142 | O-linked_Glycosylation | RAWNPFRSKLAAAIL EECCHHHHHHHHHHH | 32.19 | 23301498 | |
143 | Ubiquitination | AWNPFRSKLAAAILG ECCHHHHHHHHHHHC | 37.58 | 32015554 | |
143 | Sumoylation | AWNPFRSKLAAAILG ECCHHHHHHHHHHHC | 37.58 | - | |
143 | Sumoylation | AWNPFRSKLAAAILG ECCHHHHHHHHHHHC | 37.58 | 28112733 | |
143 | Acetylation | AWNPFRSKLAAAILG ECCHHHHHHHHHHHC | 37.58 | 25953088 | |
148 | Ubiquitination | RSKLAAAILGGVDQI HHHHHHHHHCCCCEE | 2.93 | 22817900 | |
149 | Ubiquitination | SKLAAAILGGVDQIH HHHHHHHHCCCCEEE | 4.13 | 22817900 | |
157 | Ubiquitination | GGVDQIHIKPGAKVL CCCCEEEECCCCEEE | 6.51 | 21890473 | |
158 | Sumoylation | GVDQIHIKPGAKVLY CCCEEEECCCCEEEE | 24.20 | 28112733 | |
158 | Acetylation | GVDQIHIKPGAKVLY CCCEEEECCCCEEEE | 24.20 | 25953088 | |
158 | Sumoylation | GVDQIHIKPGAKVLY CCCEEEECCCCEEEE | 24.20 | - | |
158 | Ubiquitination | GVDQIHIKPGAKVLY CCCEEEECCCCEEEE | 24.20 | 21906983 | |
161 | Ubiquitination | QIHIKPGAKVLYLGA EEEECCCCEEEEEEC | 13.81 | 22817900 | |
162 | Ubiquitination | IHIKPGAKVLYLGAA EEECCCCEEEEEECC | 38.39 | 22817900 | |
204 | Ubiquitination | GRDLINLAKKRTNII CHHHHHHHHHHCCEE | 15.73 | 22817900 | |
205 | Acetylation | RDLINLAKKRTNIIP HHHHHHHHHHCCEEC | 46.05 | 30540930 | |
205 | Ubiquitination | RDLINLAKKRTNIIP HHHHHHHHHHCCEEC | 46.05 | 30540930 | |
205 | 2-Hydroxyisobutyrylation | RDLINLAKKRTNIIP HHHHHHHHHHCCEEC | 46.05 | - | |
206 | Ubiquitination | DLINLAKKRTNIIPV HHHHHHHHHCCEECC | 59.87 | 22817900 | |
206 | Acetylation | DLINLAKKRTNIIPV HHHHHHHHHCCEECC | 59.87 | 25953088 | |
208 | Phosphorylation | INLAKKRTNIIPVIE HHHHHHHCCEECCCC | 39.38 | 20068231 | |
222 | Ubiquitination | EDARHPHKYRMLIAM CCCCCHHHHHHHHHH | 38.72 | - | |
227 | Ubiquitination | PHKYRMLIAMVDVIF HHHHHHHHHHHHEEE | 1.37 | 22505724 | |
235 | Ubiquitination | AMVDVIFADVAQPDQ HHHHEEECCCCCCCC | 10.15 | 21963094 | |
261 | Ubiquitination | LRNGGHFVISIKANC EEECCEEEEEEEECC | 2.52 | 21890473 | |
263 | Phosphorylation | NGGHFVISIKANCID ECCEEEEEEEECCCC | 16.85 | 24719451 | |
283 | Ubiquitination | EAVFASEVKKMQQEN HHHHHHHHHHHHHHC | 7.18 | 22505724 | |
284 | Acetylation | AVFASEVKKMQQENM HHHHHHHHHHHHHCC | 38.18 | 25953088 | |
284 | 2-Hydroxyisobutyrylation | AVFASEVKKMQQENM HHHHHHHHHHHHHCC | 38.18 | - | |
284 | Ubiquitination | AVFASEVKKMQQENM HHHHHHHHHHHHHCC | 38.18 | 32015554 | |
285 | Ubiquitination | VFASEVKKMQQENMK HHHHHHHHHHHHCCC | 47.30 | - | |
286 | Sulfoxidation | FASEVKKMQQENMKP HHHHHHHHHHHCCCH | 4.05 | 28183972 | |
291 | Ubiquitination | KKMQQENMKPQEQLT HHHHHHCCCHHHHCC | 7.06 | 21963094 | |
291 | Sulfoxidation | KKMQQENMKPQEQLT HHHHHHCCCHHHHCC | 7.06 | 28183972 | |
292 | Ubiquitination | KMQQENMKPQEQLTL HHHHHCCCHHHHCCC | 55.95 | 21963094 | |
292 | Acetylation | KMQQENMKPQEQLTL HHHHHCCCHHHHCCC | 55.95 | 25953088 | |
298 | Phosphorylation | MKPQEQLTLEPYERD CCHHHHCCCCCCCCC | 28.86 | - | |
302 | Phosphorylation | EQLTLEPYERDHAVV HHCCCCCCCCCCEEE | 17.77 | - | |
317 | Ubiquitination | VGVYRPPPKVKN--- EEEECCCCCCCC--- | 57.67 | 21890473 | |
318 | Ubiquitination | GVYRPPPKVKN---- EEECCCCCCCC---- | 72.17 | 21890473 | |
318 | 2-Hydroxyisobutyrylation | GVYRPPPKVKN---- EEECCCCCCCC---- | 72.17 | - |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
Oops, there are no upstream regulatory protein records of FBRL_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of FBRL_HUMAN !! |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Acetylation | |
Reference | PubMed |
"Lysine acetylation targets protein complexes and co-regulates majorcellular functions."; Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,Olsen J.V., Mann M.; Science 325:834-840(2009). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-205, AND MASS SPECTROMETRY. | |
Phosphorylation | |
Reference | PubMed |
"Evaluation of the low-specificity protease elastase for large-scalephosphoproteome analysis."; Wang B., Malik R., Nigg E.A., Korner R.; Anal. Chem. 80:9526-9533(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-124, AND MASSSPECTROMETRY. |